Antithymocyte Globulin at Clinically Relevant Concentrations Kills Leukemic Blasts-Reference-Cited by-同舟云学术

Antithymocyte Globulin at Clinically Relevant Concentrations Kills Leukemic Blasts

Published:2016-05 Issue:5 Volume:22 Page:815-824
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Dabas Rosy^ORCID,Lee Rachelle,Servito Maria Theresa,Dharmani-Khan Poonam,Modi Monica,van Slyke Tiffany,Luider Joanne,Durand Caylib,Larratt Loree,Brandwein Joseph,Morris Don,Daly Andrew,Khan Faisal M.,Storek Jan

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference57 articles.

1. Clinical bone marrow and blood stem cell transplantation,2004

2. A history of allogeneic hematopoietic cell transplantation;Thomas,2009

3. Graft-versus-host disease;Ferrara;Lancet,2009

4. Long-term physiological side effects after allogeneic bone marrow transplantation;Mohty;Hematology Am Soc Hematol Educ Program,2010

5. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial;Storb;Blood,1989

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pre-Transplant Total Lymphocyte Count Determines Anti-Thymocyte Globulin Exposure, Modifying Graft-versus-Host Disease Incidence and Post-Transplant Thymic Restoration: A Single-Center Retrospective Study;Journal of Clinical Medicine;2023-01-16

2. Incomplete chimerism following myeloablative and anti-thymocyte globulin-conditioned hematopoietic cell transplantation is a risk factor for relapse and chronic graft-versus-host disease;Cytotherapy;2022-12

3. Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation;Cytotherapy;2021-12

4. A biomarker-guided, prospective, phase 2 trial of pre-emptive graft-versus-host disease therapy using anti-thymocyte globulin;CYTOTHERAPY;2021

5. A biomarker-guided, prospective, phase 2 trial of pre-emptive graft-versus-host disease therapy using anti-thymocyte globulin;Cytotherapy;2021-11